Received Jun 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | 1 | UNK | — |
pain at the injection site; light headedness; exhaustion; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of injection site pain in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis. On 06-JUN-2025, the patient received the 1st dose of Shingles vaccine. In JUN-2025, an unknown time after receiving Shingles vaccine, the patient experienced injection site pain (Verbatim: pain at the injection site), light headedness (Verbatim: light headedness) and exhaustion (Verbatim: exhaustion). The outcome of the injection site pain, light headedness and exhaustion were not reported. It was unknown if the reporter considered the injection site pain, light headedness and exhaustion to be related to Shingles vaccine. It was unknown if the company considered the injection site pain, light headedness and exhaustion to be related to Shingles vaccine. Additional Information: GSK Receipt Date: 07-JUN-2025 This case was reported by a patient via interactive digital media. The patient had the first shot one day prior to the reporting and experienced light headedness, pain at the injection site, exhaustion. The patient would took it over shingles.